These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23518876)

  • 21. Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207.
    Arencibia JM; Bajo AM; Schally AV; Krupa M; Chatzistamou I; Nagy A
    Anticancer Drugs; 2002 Oct; 13(9):949-56. PubMed ID: 12394258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207.
    Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
    Eur J Cancer; 2005 Sep; 41(14):2196-202. PubMed ID: 16182122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.
    Miyazaki M; Nagy A; Schally AV; Lamharzi N; Halmos G; Szepeshazi K; Groot K; Armatis P
    J Natl Cancer Inst; 1997 Dec; 89(23):1803-9. PubMed ID: 9392622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice.
    Koppán M; Nagy A; Schally AV; Plonowski A; Halmos G; Arencibia JM; Groot K
    Prostate; 1999 Feb; 38(2):151-8. PubMed ID: 9973101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207.
    Plonowski A; Schally AV; Nagy A; Groot K; Krupa M; Navone NM; Logothetis C
    Cancer Lett; 2002 Feb; 176(1):57-63. PubMed ID: 11790454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses.
    Arencibia JM; Schally AV; Halmos G; Nagy A; Kiaris H
    Anticancer Drugs; 2001 Jan; 12(1):71-8. PubMed ID: 11272290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
    Chatzistamou L; Schally AV; Nagy A; Armatis P; Szepeshazi K; Halmos G
    Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis.
    Szepeshazi K; Schally AV; Nagy A; Halmos G; Groot K
    Anticancer Drugs; 1997 Nov; 8(10):974-87. PubMed ID: 9436641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system.
    Günthert AR; Gründker C; Bongertz T; Schlott T; Nagy A; Schally AV; Emons G
    Am J Obstet Gynecol; 2004 Oct; 191(4):1164-72. PubMed ID: 15507937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice.
    Miyazaki M; Schally AV; Nagy A; Lamharzi N; Halmos G; Szepeshazi K; Armatis P
    Am J Obstet Gynecol; 1999 May; 180(5):1095-103. PubMed ID: 10329861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy.
    Szepeshazi K; Schally AV; Halmos G
    Int J Oncol; 2007 Jun; 30(6):1485-92. PubMed ID: 17487370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [DLys(6)]-luteinizing hormone releasing hormone-curcumin conjugate inhibits pancreatic cancer cell growth in vitro and in vivo.
    Aggarwal S; Ndinguri MW; Solipuram R; Wakamatsu N; Hammer RP; Ingram D; Hansel W
    Int J Cancer; 2011 Oct; 129(7):1611-23. PubMed ID: 21484797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.
    Emons G; Sindermann H; Engel J; Schally AV; Gründker C
    Neuroendocrinology; 2009; 90(1):15-8. PubMed ID: 19521066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.
    Kidd M; Schally AV; Pfragner R; Malfertheiner MV; Modlin IM
    Cancer; 2008 Mar; 112(6):1404-14. PubMed ID: 18224665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207.
    Kahán Z; Nagy A; Schally AV; Halmos G; Arencibia JM; Groot K
    Cancer; 1999 Jun; 85(12):2608-15. PubMed ID: 10375109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness.
    Arencibia JM; Schally AV; Krupa M; Bajo AM; Nagy A; Szepeshazi K; Plonowski A
    Int J Oncol; 2001 Sep; 19(3):571-7. PubMed ID: 11494038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro.
    Jaszberenyi M; Schally AV; Block NL; Zarandi M; Cai RZ; Vidaurre I; Szalontay L; Jayakumar AR; Rick FG
    Target Oncol; 2013 Dec; 8(4):281-90. PubMed ID: 23371031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
    Costa B; Bendinelli S; Gabelloni P; Da Pozzo E; Daniele S; Scatena F; Vanacore R; Campiglia P; Bertamino A; Gomez-Monterrey I; Sorriento D; Del Giudice C; Iaccarino G; Novellino E; Martini C
    PLoS One; 2013; 8(8):e72281. PubMed ID: 23977270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toosendanin Exerts an Anti-Cancer Effect in Glioblastoma by Inducing Estrogen Receptor β- and p53-Mediated Apoptosis.
    Cao L; Qu D; Wang H; Zhang S; Jia C; Shi Z; Wang Z; Zhang J; Ma J
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tumor effects of peptide analogs targeting neuropeptide hormone receptors on mouse pheochromocytoma cells.
    Ziegler CG; Ullrich M; Schally AV; Bergmann R; Pietzsch J; Gebauer L; Gondek K; Qin N; Pacak K; Ehrhart-Bornstein M; Eisenhofer G; Bornstein SR
    Mol Cell Endocrinol; 2013 May; 371(1-2):189-94. PubMed ID: 23267837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.